BeOne Medicines adds $300M to New Jersey facility, topping $1B total
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
July 23, 2026 6:00 AM EDT$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities
Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE:... More
